Intervention not reported
Recurrence (loco‐regional) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Recurrence (distance) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Incidence of a secondary primary breast cancer (e.g. in the contralateral breast) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)/unknown) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
Intervention not reported
Prevention: incidence of invasive breast cancer and DCIS ‐ tamoxifen · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor) or not receiving endocrine therapy…
1 finding from 1 review
Maternal anxiety3 · Fetal ultrasound assessment before 24 weeks' gestation
First trimester routine probably leads to lower maternal anxiety3 compared with selective ultrasound (moderate certainty).
1 finding from 1 review
Preterm birth less than 34 weeks' gestation · Fetal ultrasound assessment before 24 weeks' gestation
1 finding from 1 review
Perinatal loss · Fetal ultrasound assessment before 24 weeks' gestation
First trimester routine showed no clear difference in perinatal loss compared with selective ultrasound (low certainty).
1 finding from 1 review
Induction of labour for post‐maturity · Fetal ultrasound assessment before 24 weeks' gestation
First trimester routine showed no clear difference in induction of labour for post‐maturity compared with selective ultrasound (low certainty).
1 finding from 1 review
Termination for major abnormality · Fetal ultrasound assessment before 24 weeks' gestation
1 finding from 1 review
Preterm birth less than 34 weeks' gestation · Fetal ultrasound assessment before 24 weeks' gestation
1 finding from 1 review
Perinatal loss · Fetal ultrasound assessment before 24 weeks' gestation
Second trimester routine showed no clear difference in perinatal loss compared with selective ultrasound (moderate certainty).
1 finding from 1 review
Induction of labour for post‐maturity · Fetal ultrasound assessment before 24 weeks' gestation
Second trimester routine probably leads to lower induction of labour for post‐maturity compared with selective ultrasound (moderate certainty).
1 finding from 1 review
Termination of pregnancy for fetal abnormality · Fetal ultrasound assessment before 24 weeks' gestation
Second trimester routine probably leads to higher termination of pregnancy for fetal abnormality compared with selective ultrasound (moderate certainty).
1 finding from 1 review
Maternal anxiety · Fetal ultrasound assessment before 24 weeks' gestation
1 finding from 1 review
Lesion progression · Children and/or adults with permanent or primary teeth, vital (sensitive) pulps, and cavitated or dentine carious lesions conventionally…
1 finding from 1 review
Failure of therapy · Children and/or adults with permanent or primary teeth, vital (sensitive) pulps, and cavitated or dentine carious lesions conventionally…
It is very uncertain whether sealing using sealant materials changes failure of therapy compared with non-selective carious tissue removal and conventional restoration (CR) (very low certainty).
1 finding from 1 review
Kidney failure · proteinuric chronic kidney disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hyperkalaemia · proteinuric chronic kidney disease
Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in hyperkalaemia compared with selective aldosterone antagonist (low certainty).
1 finding from 1 review
Death · proteinuric chronic kidney disease
Non‐steroidal mineralocorticoid receptor antagonist showed no clear difference in death compared with selective aldosterone antagonist (low certainty).
1 finding from 1 review